Medicine ex-warehouse analysis supervision method and system based on Internet of Things equipment

Abstract

The invention provides a medicine ex-warehouse analysis and supervision method and system based on Internet of Things equipment, and belongs to the technical field of supervision, and the method specifically comprises the steps: when the verification processing delay of a verification processing strategy does not meet the requirement, carrying out the verification processing through the attention physical index data and ex-warehouse data of a medicine and other medicines during the combined use, according to the method, the updating result of the verification processing strategy of the medicine and other medicines in the Internet of Things equipment is determined, the verification target of the medicine in patients with different inspection data in the Internet of Things equipment is determined on the basis of the verification processing strategy of the medicine and other medicines in the Internet of Things equipment, and the reliability of identification processing of joint use taboo is improved.

Description

Technical Field

[0001] The present invention belongs to the field of supervision technology, and in particular relates to a drug delivery analysis and supervision method and system based on Internet of Things devices. Background Art

[0002] There may be some contraindications in the process of joint configuration of drugs, such as liver damage, rash, allergies, etc. Therefore, it is necessary to use IoT devices to monitor, analyze and process the drugs during the joint configuration process, so as to timely discover the contraindications for joint use. Specifically, a similar technical solution is given in the invention patent application CN202510918895.5 "A terminal data management method and system for pharmaceutical sales".

[0003] However, in the actual configuration process, when facing different patients, there may be patients with abnormal indicators when the drug is used in combination with other drugs. Therefore, how to use the data of patients with abnormal indicators to determine the identification scheme of the contraindications for the combined use of the drug with other drugs, thereby improving the efficiency and reliability of the identification and processing of contraindications for the combined use of the drug with other drugs has become a technical problem that needs to be solved urgently.

[0004] In order to solve the above technical problems, the present application provides a method and system for drug delivery analysis and supervision based on Internet of Things devices. Summary of the Invention

[0005] To achieve the purpose of the present invention, the present invention adopts the following technical solutions: Specifically, this application provides a drug delivery analysis and supervision method based on IoT devices, which specifically includes: S1 determines the combined configuration data of the drug and other drugs based on the IoT code scanning device, and uses the combined configuration data as a basis to determine patients with abnormal indicators during the combined configuration process of the drug. Based on the data of patients with abnormal indicators, a verification and processing strategy for IoT devices is determined that contraindicates the combined use of the drugs; S2: when the verification delay of the verification processing strategy does not meet the requirement, determining the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device based on the relevant physical indicator data and the outbound data when the drug is used in combination with other drugs; S3 determines the verification target of the drug in the Internet of Things device for patients with different examination data based on the verification processing strategy of the drug and other drugs in the Internet of Things device.

[0006] The beneficial effects of the present invention are: The verification and processing strategy of IoT devices for drug contraindications for combined use is determined based on the data of patients with abnormal indicators, thereby realizing the determination of the verification and processing strategy of IoT devices for drug contraindications for combined use from the perspective of patients with abnormal indicators, ensuring the reliability of the identification and processing of drug contraindications for combined use in the process of combined use of drugs with a large number of patients with abnormal indicators, and also ensuring the efficiency of the identification and processing of drug contraindications for combined use.

[0007] Based on the verification and processing strategy of drugs and other drugs in IoT devices, the verification targets of drugs in IoT devices in patients with different examination data are determined, thereby avoiding the technical problem of poor recognition reliability caused by the single use of fixed contraindication features for analysis and processing of contraindications for combined use of drugs with other drugs. By conducting secondary verification processing in patients with a large number of examination items, the reliability of the verification processing is further improved, and at the same time, the reliable update processing of fixed contraindication features that have not been updated in time is guaranteed, that is, the fixed contraindication features are updated in time when new combined use contraindication features are discovered.

[0008] Furthermore, the combined configuration data of the drug and other drugs includes data on simultaneous use of the drug and other drugs in different patients.

[0009] Furthermore, the patient with abnormal indicators during the combined configuration of the drug is a patient whose physical indicators do not meet the contraindications for the combined use of the drug and other drugs during the combined use.

[0010] Furthermore, the method for determining the verification processing strategy of the Internet of Things device that is contraindicated for the combined use of the drugs is as follows: Based on the data of patients with abnormal indicators, determine patients with abnormal indicators when the drug is used in combination with other drugs; Based on other drug data of patients with abnormal indicators, determine the verification and processing strategy of the Internet of Things devices that are contraindicated for combined use of the drugs.

[0011] Furthermore, when the number of patients with abnormal indicators when the drug is used in combination with other drugs meets the requirements, then when the drug is used in combination with other drugs with patients with abnormal indicators, the verification and processing of the contraindications for combined use are performed in both the Internet of Things scanning device and the monitoring device. In other cases, the verification and processing of the contraindications for combined use only needs to be performed in the Internet of Things scanning device.

[0012] Furthermore, the method for determining the verification target of the drug in the Internet of Things device for patients with different examination data is as follows: Based on the verification processing strategy of the drug and other drugs in the IoT device, determine other drugs that only need to be verified for contraindications for combined use in the IoT scanning device, and treat them as analytical deviation drugs; Determine the number of joint shipments of the drug and the drug with the analytical deviation based on the joint shipment data of the drug with the analytical deviation; By utilizing the joint outbound delivery times and analyzing the deviation drug data, the verification targets of the drugs in the Internet of Things devices for patients with different examination data are determined.

[0013] In a second aspect, the present invention provides a computer system comprising: a memory and a processor in communication connection, and a computer program stored in the memory and capable of running on the processor, wherein the processor executes the above-mentioned method for analyzing and supervising drug shipments based on Internet of Things devices when running the computer program.

[0014] Other features and advantages will be described in the following description. The objectives and other advantages of the present invention are realized and obtained by the structures particularly pointed out in the description and drawings.

[0015] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, preferred embodiments are given below and described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The above and other features and advantages of the present invention will become more apparent by describing in detail exemplary embodiments thereof with reference to the accompanying drawings.

[0017] Figure 1 It is a flow chart of a drug delivery analysis and supervision method based on IoT devices; Figure 2 A flowchart of a method for determining a verification processing strategy for an IoT device that is contraindicated for combined use of drugs; Figure 3 A flowchart for determining whether the verification processing delay of the verification processing strategy does not meet the requirements; Figure 4 is a flow chart of a method for determining an update result of a verification processing strategy for a drug and other drugs in an Internet of Things device; Figure 5 It is a framework diagram of a computer system. DETAILED DESCRIPTION

[0018] To help those skilled in the art better understand the technical solutions in this specification, the following will provide a clear and complete description of the technical solutions in the embodiments of this specification, in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of this specification, not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this specification without creative work should fall within the scope of protection of this specification.

[0019] In this application, some drugs are checked in the Internet of Things scanning device during joint use, specifically including: the Internet of Things scanning device outputs the scanning results to the computer system, and the computer system uses fixed joint use contraindications to verify the drugs and other drugs. Some drugs are checked in the monitoring device during joint use, specifically including: the monitoring device determines the drugs shipped out based on the actual drugs shipped out and the monitoring images of other drugs, and uses the drugs shipped out, the patient's medical records, and the examination data as the input of the big model, and determines whether there are any usage contraindications based on the output results of the big model. The big model is called through the API interface, thereby avoiding the impact of computer analysis jams on the efficiency of drug shipment, and realizing seamless contraindication verification processing.

[0020] Example 1 like Figure 1 As shown, this application provides a drug delivery analysis and supervision method based on IoT devices, which specifically includes: S1 determines the combined configuration data of the drug and other drugs based on the IoT code scanning device, and uses the combined configuration data as a basis to determine patients with abnormal indicators during the combined configuration process of the drug. Based on the data of patients with abnormal indicators, a verification and processing strategy for IoT devices is determined that contraindicates the combined use of the drugs; Specifically, the Internet of Things code scanning device is a device for scanning the QR code of medicines.

[0021] Furthermore, the combined configuration data of the drug and other drugs includes data on simultaneous use of the drug and other drugs in different patients.

[0022] Specifically, the patient with abnormal indicators during the combined configuration of the drug is a patient whose physical indicators do not meet the contraindications for the combined use of the drug and other drugs during the combined use.

[0023] For example, when using nephrotoxic drugs together (such as aminoglycosides + ACEI), the contraindications for combined use include: blood creatinine >265μmol / L; when using ACEI / ARB + ​​potassium-sparing diuretics / penicillin together, the contraindications for combined use include: blood potassium >5.5mmol / L, blood creatinine increase >30%, systolic blood pressure <90 mmHg, glomerular filtration rate <60ml / min / 1.73m², urine volume <400ml / day. When there are physical indicators that do not meet the contraindications for combined use, the patient is determined to be a patient with abnormal indicators.

[0024] It should be noted that the Internet of Things devices include monitoring devices and Internet of Things scanning devices. In order to improve the efficiency of drug outbound delivery, verification is carried out in the Internet of Things scanning devices. Specifically, the Internet of Things scanning devices output the scanning results to the computer system, and the computer system uses fixed joint use contraindications to verify the drugs and other drugs. Verification is carried out in the monitoring device. Specifically, the monitoring device determines the drugs to be shipped out based on the monitoring images of the actual drugs shipped out and other drugs, and uses the drugs shipped out, the patient's medical records, and the examination data as the input of the large model. Based on the output results of the large model, it is determined whether there are any usage contraindications. The large model is called through the API interface to realize seamless contraindication verification processing.

[0025] Specifically, such as Figure 2 As shown, the method for determining the verification processing strategy of the Internet of Things device for the contraindications of the combined use of the drugs is: Based on the data of patients with abnormal indicators, determine patients with abnormal indicators when the drug is used in combination with other drugs; Other drugs for patients with abnormal indicators are regarded as risky drugs. Based on the combined use data of the risky drugs and the drugs, the verification and processing strategy of the Internet of Things devices that are contraindicated for the combined use of the drugs is determined.

[0026] In a possible embodiment, when the data on the combined use of the risky drug and the drug does not meet the requirements, that is, when the outbound volume is large, the verification and processing strategy of the Internet of Things device that determines the contraindications for the combined use of the drug is to perform verification and processing of the contraindications for combined use in both the Internet of Things scanning device and the monitoring device.

[0027] In a possible embodiment, when the number of patients who use the risky drug in combination with the drug accounts for more than 0.6 of the number of patients who use the drug, it is determined that the data on the combined use of the risky drug and the drug does not meet the requirements.

[0028] It should also be noted that when the data on the combined use of the risky drug and the drug meets the requirements, then when the drug is used in combination with other drugs for patients with abnormal indicators, the verification and processing of the contraindications for combined use will be carried out in both the IoT scanning device and the monitoring device. In other cases, the verification and processing of the contraindications for combined use only needs to be carried out in the IoT scanning device.

[0029] S2: when the verification delay of the verification processing strategy does not meet the requirement, determining the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device based on the body index data of the drug when used in combination with other drugs and the joint delivery data; Specifically, such as Figure 3 As shown, it is determined that the verification processing delay of the verification processing strategy does not meet the requirements, specifically including: Based on the historical data of the verification and analysis process, determine the number of times that the drug and the co-prepared drug have been released from the warehouse but the analysis of the contraindications for combined use has not been completed in the monitoring device, and use this as the number of delayed verifications; Based on the number of delayed verifications among different drugs, determine the drugs with delayed verification processing; Determine whether the verification processing delay of the verification processing strategy meets the requirements based on the drug data with verification processing delay and the number of delayed checks on different dates.

[0030] It can be understood that the drugs with verification processing delays are drugs that have had delayed verification a number of times in history.

[0031] Furthermore, when the average value of the number of delayed checks on different dates does not meet the requirement, it is determined that the verification processing delay of the verification processing strategy does not meet the requirement.

[0032] It can also be understood that when the average number of delayed checks on different dates meets the requirements, if the average number of delayed checks on different dates is not within the preset range, the number of delayed checks is small, and it is determined that the verification processing delay of the verification processing strategy meets the requirements.

[0033] Furthermore, if the average number of delayed verifications on different dates is within a preset range, then if the number of drugs with delayed verification processing does not meet the requirements, it is determined that the verification processing delay of the verification processing strategy does not meet the requirements; in other cases, it is determined that the verification processing delay of the verification processing strategy meets the requirements.

[0034] In one possible embodiment, if the average number of delayed verifications on different dates is between 5 and 10, then the average number of delayed verifications on different dates is determined to be within a preset range. If the average number of delayed verifications on different dates is greater than 10, then the average number of delayed verifications on different dates is determined to not meet the requirement. Specifically, if the number of drugs with delayed verification is not less than 5, then the number of drugs with delayed verification is determined to not meet the requirement.

[0035] Further, such as Figure 4 As shown, the method for determining the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device is: Using the contraindications data for the combined use of the drug and other drugs, determine the physical indicators that require attention when the drug is used in combination with other drugs, and use them as associated physical indicators; Determine, based on the joint shipment data, the number of joint shipments of the drug and other drugs on different dates, and determine, based on the joint shipment number, a proportion of the joint shipment number of the other drugs; Based on the proportion of joint outbound shipments of different other drugs and related physical indicators, the update results of the verification and processing strategy for drugs and other drugs in the Internet of Things device are determined.

[0036] Specifically, when the proportion of the number of joint shipments of different other drugs is less than the preset proportion threshold, it means that the distribution of the joint shipment of the drug and different other drugs is relatively discrete. Therefore, on this basis, it is determined that the verification and processing strategy of the drug and other drugs in the Internet of Things device still only requires verification and processing of the contraindications of joint use in the Internet of Things scanning device.

[0037] Furthermore, when the proportion of the number of joint shipments of different other drugs is less than a preset proportion threshold, the number of associated physical indicators of the other drugs is determined. When the number of associated physical indicators of the other drugs meets the requirement, the verification processing strategy of the drug and other drugs in the IoT device is determined to only require the joint use contraindication verification processing in the IoT code scanning device; It should also be noted that when the number of associated physical indicators of the other drugs does not meet the requirements, it is also necessary to determine the number of associated physical indicators of the other drugs and the proportion of the number of joint outbound shipments. If the number of associated physical indicators of the other drugs and the proportion of the number of joint outbound shipments are both within the preset range, the verification and processing strategy for the drugs and other drugs in the Internet of Things device is to only perform verification and processing of joint use contraindications in the Internet of Things scanning device. In other cases, it is determined that verification and processing of joint use contraindications are performed in both the Internet of Things scanning device and the monitoring device.

[0038] Furthermore, the contraindication data for combined use is determined based on the analysis results of the drug instructions.

[0039] S3 determines the verification target of the drug in the Internet of Things device for patients with different examination data based on the verification processing strategy of the drug and other drugs in the Internet of Things device.

[0040] It should be noted that the patient's examination data includes the number of examination items of the patient and the examination results of the examination items. The examination items specifically include blood pressure, pulse, blood routine, blood biochemistry examination including liver function (transaminase, bilirubin), kidney function (creatinine, urea nitrogen), blood sugar, blood lipids (cholesterol, triglycerides), urine routine: detection of urine protein, urine sugar, white blood cells, etc., diagnosis of kidney disease or urinary tract infection, ultrasound: examination of the morphology of organs such as liver, gallbladder, pancreas, spleen, and kidneys, X-ray / CT / MRI: assessment of structural abnormalities such as fractures and tumors, electrocardiogram: recording cardiac electrical activity, diagnosis of diseases such as arrhythmia, liver function: detection of indicators such as alanine aminotransferase and aspartate aminotransferase, assessment of liver function, kidney function: detection of indicators such as creatinine and urea nitrogen, reflecting the kidney filtration function.

[0041] Specifically, the method for determining the verification target of the drug in the IoT device for patients with different examination data is as follows: Based on the verification processing strategy of the drug and other drugs in the IoT device, determine other drugs that only need to be verified for contraindications for combined use in the IoT scanning device, and treat them as analytical deviation drugs; Determine the number of joint shipments of the drug and the drug with the analytical deviation based on the joint shipment data of the drug with the analytical deviation; By utilizing the joint outbound delivery times and analyzing the deviation drug data, the verification targets of the drugs in the Internet of Things devices for patients with different examination data are determined.

[0042] It should be noted that when the analytical deviation drug does not meet the requirements, at this time, due to the deviation in the contraindications for combined use of the drugs, a secondary verification of the contraindications for combined use is performed in the monitoring device on the basis that the examination data of the patients who use the drugs in combination with the analytical deviation drugs meet the requirements.

[0043] In a possible embodiment, when the proportion of the analytical deviation drug in other drugs used in combination with the drug is greater than 0.4, it is determined that the analytical deviation drug does not meet the requirements. At this time, if the number of examination items of patients who use the drug in combination with the analytical deviation drug is not less than 3, it is determined that the examination data of patients who use the drug in combination with the analytical deviation drug meet the requirements.

[0044] It should also be noted that when the analytical deviation drug meets the requirements, it is necessary to further determine the number of times the drug and the analytical deviation drug are jointly shipped out. When the average daily number of times the drug and the analytical deviation drug are jointly shipped out does not meet the requirements, the shipment volume of the analytical deviation drug at this time is large. Therefore, on the basis that the examination data of the patients who use the drug in combination with the analytical deviation drug meets the requirements, a secondary verification process of the contraindications for combined use is performed in the monitoring device.

[0045] In a possible embodiment, when the average daily number of joint shipments of the drug and the drug with analytical deviation is more than 20 times, it is determined that the average daily number of joint shipments of the drug and the drug with analytical deviation does not meet the requirement.

[0046] Furthermore, when the average daily number of joint shipments of the drug and the analytical deviation drug meets the requirements, if the drug has joint shipment data with the analytical deviation drug on different dates, then on the basis that the examination data of the patients who use the drug in combination with the analytical deviation drug meet the requirements, a secondary verification process of the contraindications for joint use is performed in the monitoring device. If the drug does not have joint shipment data with the analytical deviation drug on different dates, then the number of times the analytical deviation drug is subjected to a secondary verification process of the contraindications for joint use in the monitoring device on the current date is less than a preset number threshold, then on the basis that the examination data of the patients who use the drug in combination with the analytical deviation drug meet the requirements, a secondary verification process of the contraindications for joint use is performed in the monitoring device.

[0047] Example 2 Second, as Figure 5 As shown, the present invention provides a computer system, comprising: a memory and a processor that are communicatively connected, and a computer program stored on the memory and capable of running on the processor, wherein the processor executes the above-mentioned method for analyzing and supervising drug shipments based on Internet of Things devices when running the computer program.

[0048] Optionally, the method for determining the verification target of the drug in the IoT device for patients with different examination data is: Based on the verification processing strategy of the drug and other drugs in the IoT device, determine other drugs that only need to be verified for contraindications for combined use in the IoT scanning device, and treat them as analytical deviation drugs; Determine the number of joint shipments of the drug and the drug with the analytical deviation based on the joint shipment data of the drug with the analytical deviation; The number of joint outbound shipments is used to determine the verification targets of the drugs in IoT devices for patients with different examination data.

[0049] Optionally, at this time, if the drug has joint delivery data with the analytical deviation drug on different dates, then on the basis that the examination data of the patients who use the drug in combination with the analytical deviation drug meet the requirements, a secondary verification process of the contraindications for combined use is performed in the monitoring device. If the drug does not have joint delivery data with the analytical deviation drug on different dates, then at this time, when the number of analytical deviation drugs that have been secondary verified for contraindications for combined use in the monitoring device on the current date is less than a preset number threshold, then on the basis that the examination data of the patients who use the drug in combination with the analytical deviation drug meet the requirements, a secondary verification process of the contraindications for combined use is performed in the monitoring device.

[0050] In a possible embodiment, when the number of times that analytical deviation drugs are subjected to secondary verification processing for combined use contraindications in the monitoring device on the current date is less than 30 times, secondary verification processing for combined use contraindications is performed in the monitoring device on the basis that the examination data of patients who use the drugs in combination with the analytical deviation drugs meet the requirements.

[0051] Example 3 Specifically, the method for determining the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device is: Using the contraindications data for the combined use of the drug and other drugs, determine the physical indicators that require attention when the drug is used in combination with other drugs, and use them as associated physical indicators; Determine the number of times the drug is jointly shipped with other drugs on different dates based on the joint shipment data; Based on the associated physical indicators and the number of times the drug is jointly shipped out with other drugs on different dates, an update result of a verification processing strategy for the drug and other drugs in an Internet of Things device is determined.

[0052] It should be noted that the number of times the drug is jointly shipped out with other drugs on different dates is determined. If the average number of times the drug is jointly shipped out with other drugs on different dates meets the requirements, it means that the number of times the drug is shipped out together with other drugs is small. On this basis, there is no need to update the verification and processing strategy for all other drugs that are used in combination with the drug, and the verification and processing shall still be carried out according to the original verification and processing strategy.

[0053] In a possible embodiment, when the average number of times the drug is jointly shipped out with other drugs on different dates is less than 30 times, it is determined that the average number of times the drug is jointly shipped out with other drugs on different dates meets the requirements.

[0054] It is understandable that if the average number of times the drug and other drugs are jointly shipped out on different dates does not meet the requirements, at this time when the drug and other drugs only need to be checked for contraindications for joint use in the Internet of Things scanning device, then the verification and processing strategy for the drug and other drugs in the Internet of Things device still only needs to be checked for contraindications for joint use in the Internet of Things scanning device.

[0055] Furthermore, when the drug and other drugs only need to be checked for contraindications for joint use in the Internet of Things scanning device, the verification processing strategy for determining the drug and other drugs in the Internet of Things device still only needs to be checked for contraindications for joint use in the Internet of Things scanning device.

[0056] In addition, it can be understood that when the drug and other drugs do not belong to the categories that only require verification and processing of joint use contraindications in the Internet of Things scanning device, the ratio of the number of joint shipments of the drug and different other drugs to the number of joint shipments of the drug and other drugs is obtained, and it is used as the ratio of the number of joint shipments of other drugs. When the ratio of the number of joint shipments of different other drugs is less than the preset ratio threshold, it means that the distribution of the joint shipment of the drug and different other drugs is relatively discrete. Therefore, on this basis, it is determined that the verification and processing strategy of the drug and other drugs in the Internet of Things device still belongs to the category that only requires verification and processing of joint use contraindications in the Internet of Things scanning device.

[0057] In a possible embodiment, when the proportions of the number of joint shipments of different other drugs are all less than 0.1, it is determined that the proportions of the number of joint shipments of different other drugs are all less than a preset proportion threshold.

[0058] Furthermore, when the proportion of the number of times different other drugs are jointly shipped out is less than a preset proportion threshold, the number of associated physical indicators of the other drugs is determined. When the number of associated physical indicators of the other drugs meets the requirement, that is, there is only one, the verification processing strategy of the drug and other drugs in the IoT device is determined to only require the verification processing of the joint use contraindication in the IoT code scanning device; It should also be noted that when the number of associated physical indicators of the other drugs does not meet the requirements, it is also necessary to determine the number of associated physical indicators of the other drugs and the proportion of the number of joint outbound shipments. If the number of associated physical indicators of the other drugs and the proportion of the number of joint outbound shipments are both within the preset range, the verification and processing strategy for the drugs and other drugs in the Internet of Things device is to only perform verification and processing of joint use contraindications in the Internet of Things scanning device. In other cases, it is determined that verification and processing of joint use contraindications are performed in both the Internet of Things scanning device and the monitoring device.

[0059] In a possible embodiment, if the number of associated physical indicators of the other drugs is less than 2 and the proportion of joint delivery times is between 0.1 and 0.2, then the verification processing strategy for the drug and other drugs in the Internet of Things device is determined to be that only the verification processing of joint use contraindications needs to be performed in the Internet of Things scanning device.

[0060] Example 4 Specifically, the method for determining the verification processing strategy of the Internet of Things device that is contraindicated for the combined use of the drugs is as follows: Based on the data of patients with abnormal indicators, determine patients with abnormal indicators when the drug is used in combination with other drugs; Based on other drug data of patients with abnormal indicators, determine the verification and processing strategy of the Internet of Things devices that are contraindicated for combined use of the drugs.

[0061] It can be understood that when the drug is used in combination with other drugs, and there are patients with abnormal indicators in different other drugs, the verification and processing strategy of the Internet of Things device that determines the contraindications for the combined use of the drugs is to perform verification and processing of the contraindications for combined use in both the Internet of Things scanning device and the monitoring device.

[0062] In addition, it can be understood that when the drug is used in combination with other drugs, there are not all patients with abnormal indicators in different other drugs, then the number of patients with abnormal indicators in the process of using the drug in combination with other drugs is obtained. When the number of patients with abnormal indicators in the process of using the drug in combination with other drugs does not meet the requirements, the verification and processing strategy of the Internet of Things device that determines the contraindications for the combined use of the drugs is to perform verification and processing of the contraindications for combined use in both the Internet of Things scanning device and the monitoring device.

[0063] In a possible embodiment, when the ratio of the number of patients with abnormal indicators during the combined use of the drug with other drugs to the number of patients using the drug with other drugs is greater than 0.2, it is determined that the number of patients with abnormal indicators during the combined use of the drug with other drugs does not meet the requirements.

[0064] Furthermore, when the number of patients with abnormal indicators when the drug is used in combination with other drugs meets the requirements, then when the drug is used in combination with other drugs with patients with abnormal indicators, the verification and processing of the contraindications for combined use are performed in both the Internet of Things scanning device and the monitoring device. In other cases, the verification and processing of the contraindications for combined use only needs to be performed in the Internet of Things scanning device.

[0065] The various embodiments in this specification are described in a progressive manner. Similar portions between the various embodiments can be referenced to each other, and each embodiment focuses on the differences from the other embodiments. In particular, the device, apparatus, and non-volatile computer storage medium embodiments are generally similar to the method embodiments, so their descriptions are relatively simplified. For relevant details, refer to the descriptions of the method embodiments.

[0066] The foregoing description of this specification describes specific embodiments. Other embodiments are within the scope of the appended claims. In some cases, the actions or steps recited in the claims can be performed in an order different from that described in the embodiments and still achieve the desired results. Furthermore, the processes depicted in the accompanying drawings do not necessarily require the specific order shown or the sequential order to achieve the desired results. In certain embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0067] The foregoing description is merely one or more embodiments of this specification and is not intended to limit this specification. It will be apparent to those skilled in the art that various modifications and variations may be made to one or more embodiments of this specification. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of one or more embodiments of this specification are intended to be within the scope of the claims of this specification.

Claims

1. A drug delivery analysis and supervision method based on Internet of Things devices, characterized in that: Specifically include: Based on the IoT code scanning device, determine the joint configuration data of the drug and other drugs, and use the joint configuration data as a basis to identify patients with abnormal indicators during the joint configuration process of the drug. Based on the data of patients with abnormal indicators, determine the verification and processing strategy of the IoT device that contraindicates the joint use of the drug; When the verification delay of the verification processing strategy does not meet the requirement, the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device is determined based on the relevant body index data and the outbound data when the drug is used in combination with other drugs; Based on the verification processing strategy of the drug and other drugs in the Internet of Things device, the verification target of the drug in the Internet of Things device for patients with different examination data is determined.

2. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: The Internet of Things code scanning device is a device for scanning the QR code of medicines.

3. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: The combined configuration data of the drug and other drugs includes data on simultaneous use of the drug and other drugs in different patients.

4. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: The patient with abnormal indicators during the combined configuration of the drug is a patient whose physical indicators do not meet the contraindications for the combined use of the drug and other drugs during the combined use.

5. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: The method for determining the verification and processing strategy of the Internet of Things device for the contraindications of the combined use of the drugs is as follows: Based on the data of patients with abnormal indicators, determine patients with abnormal indicators when the drug is used in combination with other drugs; Based on other drug data of patients with abnormal indicators, determine the verification and processing strategy of the Internet of Things devices that are contraindicated for combined use of the drugs.

6. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 5 is characterized in that: When the drug is used in combination with other drugs, and there are patients with abnormal indicators in different other drugs, the verification and processing strategy of the Internet of Things device that determines the contraindications for the combined use of the drugs is to perform verification and processing of the contraindications for combined use in both the Internet of Things scanning device and the monitoring device.

7. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: The method for determining the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device is as follows: Using the contraindications data for the combined use of the drug and other drugs, determine the physical indicators that require attention when the drug is used in combination with other drugs, and use them as associated physical indicators; Determine the number of times the drug is jointly shipped with other drugs on different dates based on the joint shipment data; Based on the associated physical indicators and the number of joint shipments with other drugs on different dates, an update result of a verification processing strategy for the drug and other drugs in an Internet of Things device is determined.

8. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: When the drug and other drugs only need to be checked for contraindications for joint use in the Internet of Things scanning device, there is no need to update the verification and processing strategy for all other drugs that are used in combination with the drug, and the verification and processing can still be carried out according to the original verification and processing strategy.

9. The drug delivery analysis and supervision method based on Internet of Things devices according to claim 1 is characterized in that: The method for determining the verification target of the drug in the IoT device for patients with different examination data is as follows: Based on the verification processing strategy of the drug and other drugs in the IoT device, determine other drugs that only need to be verified for contraindications for combined use in the IoT scanning device, and treat them as analytical deviation drugs; Determine the number of joint shipments of the drug and the drug with the analytical deviation based on the joint shipment data of the drug with the analytical deviation; By utilizing the joint outbound delivery times and analyzing the deviation drug data, the verification targets of the drugs in the Internet of Things devices for patients with different examination data are determined.

10. A computer system comprising: A memory and a processor in communication connection, and a computer program stored in the memory and capable of running on the processor, characterized in that when the processor runs the computer program, a drug outbound analysis and supervision method based on an Internet of Things device as described in any one of claims 1 to 9 is executed.

Images